Merck KGaA Finds The Right Home For Disease-Modifying OA Agent In Novartis

Licenses Nanobody M6495 To Swiss Firm

Novartis has added an anti-osteoarthritic Nanobody, M6495, to its growing pipeline of candidates for the condition, in a €450m agreement with Merck KGaA that sees the latter deliver on its plans to find new homes for its osteoarthritis pipeline.  

Osteoarthritis
Reversing Osteoarthritis Changes Has Proven Difficult • Source: Shutterstock

The increasing focus of big pharma companies on specific therapeutic categories can leave promising candidates in out-of-favour conditions out in the cold, but Merck KGaA has tackled the issue head on by licensing a potentially disease-modifying osteoarthritis program to Novartis AG, in a deal valued at €450m ($527m). 

Merck KGaA has out-licensed M6495, a Phase II-ready anti-ADAMTS5 Nanobody, to Novartis for an upfront payment of €50m. The Darmstadt, Germany-headquartered company could receive a further €400m if the program...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By 

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.